Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ
2024
How Ligands Interact with PPARγ
publication
10 minutes
Evidence: high
Author Information
Author(s): Shang Jinsai, Kojetin Douglas J
Primary Institution: Vanderbilt University
Hypothesis
Covalent inhibitors weaken the binding of non-covalent ligands to PPARγ through an allosteric mechanism.
Conclusion
Covalent inhibitors GW9662 and T0070907 do not block other ligands from binding to PPARγ and can actually alter their binding modes.
Supporting Evidence
- Covalent inhibitors can change the binding modes of non-covalent ligands.
- NMR and crystallography were used to study ligand interactions.
- GW9662 and T0070907 should not be used as antagonists to block ligand binding.
Takeaway
This study shows that some drugs can change how other drugs work when they are used together, which is important for treating diseases like diabetes.
Methodology
The study used NMR spectroscopy and crystallography to analyze ligand binding to PPARγ.
Limitations
The study primarily focuses on specific ligands and may not generalize to all PPARγ ligands.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website